Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA) and maintenance therapy to prevent exacerbations by targeting the underlying pathophysiology (e.g., a LABA / ICS such as GSK’s Advair or an anti-IL-5 agent such as AstraZeneca’s Symbicort). Many pediatric asthma patients receive more than one agent for their condition. Despite the availability of multiple well-established therapies, the pediatric asthma treatment landscape has seen the approval and launch of additional agents in recent years, including novel biologics (e.g., Regeneron / Sanofi’s Dupixent) and generic versions of blockbuster inhaled drugs (e.g., albuterol sulfate and salmeterol / fluticasone propionate). These events have added more treatment options and fueled competition in this market.
Markets covered: United States
Key companies: AstraZeneca, GSK, Regeneron, Sanofi, Teva
Key drugs: Advair, Symbicort, Dulera, Breo, Dupixent, Fasenra, Nucala, Xolair, Ventolin, ProAir, albuterol sulfate, montelukast sodium, Flovent, Qvar, Spiriva
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.